查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1572977

生技藥品外包市場：按產品類型、應用、供應商、服務類型、最終用戶、治療領域 - 2025-2030 年全球預測

Biologics Outsourcing Market by Product Type, Application, Source, Service Type, End User, Therapeutic Area - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年生技藥品外包市場價值為205.6億美元，預計到2024年將達到228.7億美元，複合年成長率為12.18%，到2030年將達到459.8億美元。

生技藥品外包涉及將生物製藥的製造和開發過程委託給專業的第三方服務供應商。其範圍包括細胞株開發、製程開發、分析表徵、配方和生產等活動。這種需求源自於生物製藥，包括蛋白質、抗體和基因療法藥物，需要專門的專業知識和設備。應用範圍包括希望加快產品開發、減少內部設備資本支出以及將資源集中在核心競爭力的製藥和生物技術公司。最終用途範圍延伸至腫瘤學、自體免疫疾病和罕見遺傳疾病等治療領域。影響生技藥品外包市場的主要成長要素包括慢性病的增加、生物技術的進步以及生物製藥開發投資的增加。由於較低的營運成本和擴大的醫療基礎設施，新興市場提供了潛在的商機。抓住此類機會的建議包括與當地服務供應商建立策略聯盟以及參與技術轉移。然而，挑戰依然存在，包括嚴格的監管要求、對智慧財產權安全的擔憂以及不同的品質標準。這些因素可能會阻礙市場擴張，特別是在法律規範較不成熟的地區。儘管存在這些挑戰，一次性技術、自動化和高級分析等領域的創新在提高生技藥品生產的效率和擴充性方面具有巨大潛力。公司可以專注於開發具有成本效益的生物加工技術和個人化醫療，以保持競爭優勢。此外，數位轉型，包括人工智慧和機器學習在生技藥品研發和製造中的整合，可能會帶來重大突破。該市場的特點是充滿活力且競爭激烈，大型合約開發和受託製造廠商（CDMO）收購利基服務供應商以擴大其能力和地理範圍並加強其市場地位，這往往會導致更大的整合。

主要市場統計
基準年[2023] 205.6億美元
預測年份 [2024] 228.7億美元
預測年份 [2030] 459.8億美元
複合年成長率（%） 12.18%

市場動態：快速發展的生技藥品外包市場的關鍵市場洞察

供需的動態交互作用正在改變生技藥品外包市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 嚴格的監管要求以及生技藥品製造中合規專業知識的需求
    • 推動生技藥品製造外包的成本效益和縮短時間的優勢
    • 製藥公司擴大生技藥品管道需要外部製造支持
    • 外包公司採用一次性技術和連續生物加工
  • 市場限制因素
    • 缺乏專業生技藥品製造和工藝開發的熟練勞動力
    • 委託過程中生物製藥品質的變化導致潛在的風險和責任
  • 市場機會
    • 有機會與尋求經濟實惠的生技藥品製造解決方案的中小型生物技術公司合作
    • 利基治療領域對專業生技藥品開發服務的需求不斷成長
    • 加強製藥公司與合約研發組織在生技藥品開發上的合作
  • 市場挑戰
    • 管理生技藥品外包市場中的供應鏈中斷與物流挑戰
    • 確保生技藥品外包服務的成本效率，同時維持高品質標準

波特五力：駕馭生技藥品外包市場的策略工具

波特的五力架構是了解生技藥品外包市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點，避免潛在的挑戰，確保更強大的市場地位。

PESTLE分析：了解生技藥品外包市場的外部影響

外部宏觀環境因素在塑造生技藥品外包市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解生技藥品外包市場的競爭格局

對生技藥品外包市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣生技藥品外包市場供應商的績效評估

FPNV 定位矩陣是評估生技藥品外包市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製生技藥品外包市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對生技藥品外包市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 嚴格的監管要求以及生技藥品製造中合規專業知識的需求
      • 成本效率和縮短時間的優勢推動了生物製藥製造的外包
      • 製藥公司擴大生物製藥管道需要外部製造支持
      • 外包公司採用一次性技術和連續生物加工
    • 抑制因素
      • 專業生技藥品製造和工藝開發的熟練勞動力有限
      • 外包過程中生物製品品質的變化導致潛在的風險和責任
    • 機會
      • 有機會與尋求負擔得起的生技藥品製造解決方案的小型生物技術公司合作
      • 利基治療領域對專業生技藥品開發服務的需求不斷成長
      • 擴大製藥公司與合約研究組織在生物製藥開發的合作
    • 任務
      • 生技藥品外包市場因應供應鏈中斷與物流挑戰
      • 確保生技藥品外包服務的成本效率，同時維持高品質標準
  • 市場區隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章生技藥品外包市場：依產品類型

  • 反義、RNAi、分子治療
  • 單株抗體
  • 其他生物製藥
  • 重組蛋白
  • 疫苗

第7章生技藥品外包市場：依應用分類

  • 心血管疾病
  • 免疫學
    • 過敏性疾病
    • 自體免疫疾病
  • 感染疾病
    • 細菌感染疾病
    • 病毒感染
  • 神經病學
  • 腫瘤學
    • 癌症生物標記研究
    • 個人化癌症治療
  • 其他應用

第8章生技藥品外包市場：依來源分類

  • 哺乳動物的
  • 非哺乳動物
    • 細菌
    • 昆蟲細胞
    • 植物細胞
    • 酵母菌

第9章生技藥品外包市場：依服務類型

  • 分析和品管
  • 臨床試驗
  • 填充和整理操作
  • 製程開發
  • 監管服務

第 10 章生技藥品外包市場：依最終用戶分類

  • 生技公司
  • 合約研究組織（CRO）
  • 製藥公司
  • 調查機構

第11章依治療領域分類的生技藥品外包市場

  • 癌症
  • 心血管疾病
  • 感染疾病
  • 發炎和免疫疾病
  • 代謝紊亂
  • 神經系統疾病

第12章美洲生技藥品外包市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第13章亞太生技藥品外包市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第14章歐洲、中東和非洲生技藥品外包市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第15章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-1A1A064C0467

The Biologics Outsourcing Market was valued at USD 20.56 billion in 2023, expected to reach USD 22.87 billion in 2024, and is projected to grow at a CAGR of 12.18%, to USD 45.98 billion by 2030.

Biologics outsourcing involves externalizing the production and development processes of biologic drugs to specialized third-party service providers. The scope includes activities such as cell line development, process development, analytical characterization, formulation, and production. This necessity arises from the complex nature of biologic drugs, which include proteins, antibodies, and gene therapies, demanding specialized expertise and facilities. Applications span across pharmaceuticals and biotechnology companies aiming to expedite product development, reduce capital expenditure on in-house facilities, and focus resources on core competencies. The end-use scope extends to therapeutic areas including oncology, autoimmune diseases, and rare genetic disorders. Key growth factors influencing the biologics outsourcing market include the increasing prevalence of chronic diseases, advancements in biotechnology, and growing investment in biologic drug development. Emerging markets offer potential opportunities, driven by lower operational costs and expanding healthcare infrastructures. Recommendations for capturing these opportunities include forming strategic alliances with local service providers and engaging in technology transfers. However, challenges persist, such as stringent regulatory requirements, concerns over intellectual property security, and variability in quality standards. These factors can hinder market expansion, particularly across regions with less mature regulatory frameworks. Despite these challenges, innovation in areas such as single-use technologies, automation, and advanced analytics holds significant promise for enhancing efficiency and scalability in biologics production. Companies could focus on the development of cost-effective bioprocessing technologies and personalized medicine to maintain competitive advantage. Furthermore, digital transformation, including the integration of artificial intelligence and machine learning in biologic R&D and manufacturing, can lead to significant breakthroughs. The market is characterized by a dynamic and competitive landscape, with a trend towards consolidation, as larger contract development and manufacturing organizations (CDMOs) acquire niche service providers to expand capabilities and geographical reach, thereby strengthening their market position.

KEY MARKET STATISTICS
Base Year [2023] USD 20.56 billion
Estimated Year [2024] USD 22.87 billion
Forecast Year [2030] USD 45.98 billion
CAGR (%) 12.18%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Biologics Outsourcing Market

The Biologics Outsourcing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Stringent regulatory requirements and the need for compliance expertise in biologics production
    • Cost-efficiency and time reduction benefits driving outsourcing of biologics manufacturing
    • Expansion of biologics pipelines by pharmaceutical companies necessitating external manufacturing support
    • Adoption of single-use technologies and continuous bioprocessing by outsourcing firms
  • Market Restraints
    • Limited availability of skilled workforce for specialized biologics manufacturing and process development
    • Variability in biological product quality during outsourcing leading to potential risks and liabilities
  • Market Opportunities
    • Partnership opportunities with smaller biotechnology firms seeking affordable biologics manufacturing solutions
    • Growing need for specialized biologics development services in niche therapeutic areas
    • Rising collaboration between pharmaceutical companies and contract research organizations for biologics development
  • Market Challenges
    • Managing supply chain disruptions and logistics challenges in the biologics outsourcing market
    • Ensuring cost efficiency while maintaining high quality standards in biologics outsourcing services

Porter's Five Forces: A Strategic Tool for Navigating the Biologics Outsourcing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Biologics Outsourcing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Biologics Outsourcing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Biologics Outsourcing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Biologics Outsourcing Market

A detailed market share analysis in the Biologics Outsourcing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Biologics Outsourcing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Biologics Outsourcing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Biologics Outsourcing Market

A strategic analysis of the Biologics Outsourcing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biologics Outsourcing Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Biocon Limited, Boehringer Ingelheim GmbH, Catalent, Inc., Charles River Laboratories International, Inc., Covance Inc., Eli Lilly and Company, Fujifilm Diosynth Biotechnologies, Genentech, Inc., Icon plc, Lonza Group AG, Merck KGaA, Novartis AG, Parexel International Corporation, Pfizer Inc., Samsung Biologics Co., Ltd., Sandoz International GmbH, Thermo Fisher Scientific Inc., and WuXi AppTec Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Biologics Outsourcing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across Antisense, RNAi, And Molecular Therapy, Monoclonal Antibodies, Other Biologics, Recombinant Proteins, and Vaccines.
  • Based on Application, market is studied across Cardiovascular Diseases, Immunology, Infectious Diseases, Neurology, Oncology, and Other Applications. The Immunology is further studied across Allergic Disorders and Autoimmune Diseases. The Infectious Diseases is further studied across Bacterial Infections and Viral Infections. The Oncology is further studied across Cancer Biomarker Studies and Personalized Cancer Treatments.
  • Based on Source, market is studied across Mammalian and Non-Mammalian. The Non-Mammalian is further studied across Bacteria, Insect Cells, Plant Cells, and Yeast.
  • Based on Service Type, market is studied across Analytical And Quality Control, Clinical Trials, Fill And Finish Operations, Process Development, and Regulatory Services.
  • Based on End User, market is studied across Biotechnology Companies, Contract Research Organizations (CROs), Pharmaceutical Companies, and Research Institutes.
  • Based on Therapeutic Area, market is studied across Cancer, Cardiovascular Diseases, Infectious Diseases, Inflammatory And Immune Disorders, Metabolic Disorders, and Neurological Conditions.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Stringent regulatory requirements and the need for compliance expertise in biologics production
      • 5.1.1.2. Cost-efficiency and time reduction benefits driving outsourcing of biologics manufacturing
      • 5.1.1.3. Expansion of biologics pipelines by pharmaceutical companies necessitating external manufacturing support
      • 5.1.1.4. Adoption of single-use technologies and continuous bioprocessing by outsourcing firms
    • 5.1.2. Restraints
      • 5.1.2.1. Limited availability of skilled workforce for specialized biologics manufacturing and process development
      • 5.1.2.2. Variability in biological product quality during outsourcing leading to potential risks and liabilities
    • 5.1.3. Opportunities
      • 5.1.3.1. Partnership opportunities with smaller biotechnology firms seeking affordable biologics manufacturing solutions
      • 5.1.3.2. Growing need for specialized biologics development services in niche therapeutic areas
      • 5.1.3.3. Rising collaboration between pharmaceutical companies and contract research organizations for biologics development
    • 5.1.4. Challenges
      • 5.1.4.1. Managing supply chain disruptions and logistics challenges in the biologics outsourcing market
      • 5.1.4.2. Ensuring cost efficiency while maintaining high quality standards in biologics outsourcing services
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Biologics Outsourcing Market, by Product Type

  • 6.1. Introduction
  • 6.2. Antisense, RNAi, And Molecular Therapy
  • 6.3. Monoclonal Antibodies
  • 6.4. Other Biologics
  • 6.5. Recombinant Proteins
  • 6.6. Vaccines

7. Biologics Outsourcing Market, by Application

  • 7.1. Introduction
  • 7.2. Cardiovascular Diseases
  • 7.3. Immunology
    • 7.3.1. Allergic Disorders
    • 7.3.2. Autoimmune Diseases
  • 7.4. Infectious Diseases
    • 7.4.1. Bacterial Infections
    • 7.4.2. Viral Infections
  • 7.5. Neurology
  • 7.6. Oncology
    • 7.6.1. Cancer Biomarker Studies
    • 7.6.2. Personalized Cancer Treatments
  • 7.7. Other Applications

8. Biologics Outsourcing Market, by Source

  • 8.1. Introduction
  • 8.2. Mammalian
  • 8.3. Non-Mammalian
    • 8.3.1. Bacteria
    • 8.3.2. Insect Cells
    • 8.3.3. Plant Cells
    • 8.3.4. Yeast

9. Biologics Outsourcing Market, by Service Type

  • 9.1. Introduction
  • 9.2. Analytical And Quality Control
  • 9.3. Clinical Trials
  • 9.4. Fill And Finish Operations
  • 9.5. Process Development
  • 9.6. Regulatory Services

10. Biologics Outsourcing Market, by End User

  • 10.1. Introduction
  • 10.2. Biotechnology Companies
  • 10.3. Contract Research Organizations (CROs)
  • 10.4. Pharmaceutical Companies
  • 10.5. Research Institutes

11. Biologics Outsourcing Market, by Therapeutic Area

  • 11.1. Introduction
  • 11.2. Cancer
  • 11.3. Cardiovascular Diseases
  • 11.4. Infectious Diseases
  • 11.5. Inflammatory And Immune Disorders
  • 11.6. Metabolic Disorders
  • 11.7. Neurological Conditions

12. Americas Biologics Outsourcing Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Biologics Outsourcing Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Biologics Outsourcing Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. Biocon Limited
  • 4. Boehringer Ingelheim GmbH
  • 5. Catalent, Inc.
  • 6. Charles River Laboratories International, Inc.
  • 7. Covance Inc.
  • 8. Eli Lilly and Company
  • 9. Fujifilm Diosynth Biotechnologies
  • 10. Genentech, Inc.
  • 11. Icon plc
  • 12. Lonza Group AG
  • 13. Merck KGaA
  • 14. Novartis AG
  • 15. Parexel International Corporation
  • 16. Pfizer Inc.
  • 17. Samsung Biologics Co., Ltd.
  • 18. Sandoz International GmbH
  • 19. Thermo Fisher Scientific Inc.
  • 20. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. BIOLOGICS OUTSOURCING MARKET RESEARCH PROCESS
  • FIGURE 2. BIOLOGICS OUTSOURCING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. BIOLOGICS OUTSOURCING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. BIOLOGICS OUTSOURCING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIOLOGICS OUTSOURCING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BIOLOGICS OUTSOURCING MARKET DYNAMICS
  • TABLE 7. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY ANTISENSE, RNAI, AND MOLECULAR THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY OTHER BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY ALLERGIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CANCER BIOMARKER STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PERSONALIZED CANCER TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY OTHER APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY BACTERIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY INSECT CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PLANT CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY YEAST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY ANALYTICAL AND QUALITY CONTROL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY FILL AND FINISH OPERATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY REGULATORY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY INFLAMMATORY AND IMMUNE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY NEUROLOGICAL CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 89. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 90. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 96. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 99. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 100. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 101. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 102. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 103. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 109. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 110. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 111. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 112. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 113. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 116. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 128. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 132. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 134. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 135. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 138. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 141. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 142. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 143. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 144. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 145. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 148. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 151. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 152. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 153. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 154. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 155. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 157. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 158. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 161. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 162. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 163. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 164. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 165. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 167. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 168. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 171. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 172. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 173. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 174. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 175. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 177. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 178. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 181. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 182. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 183. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 184. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 185. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 188. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 192. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 193. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 194. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 195. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 197. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 198. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 200. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 201. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 202. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 203. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 204. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 205. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 207. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 212. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 213. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 214. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 215. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 217. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 218. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 220. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 221. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 222. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 223. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 224. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 225. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 227. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 228. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 230. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 231. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 232. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 233. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 234. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 235. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 237. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 238. VIETNAM BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. VIETNAM BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 240. VIETNAM BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 241. VIETNAM BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 242. VIETNAM BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 243. VIETNAM BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 244. VIETNAM BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 245. VIETNAM BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. VIETNAM BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 247. VIETNAM BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 259. DENMARK BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. DENMARK BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 261. DENMARK BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 262. DENMARK BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 263. DENMARK BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 264. DENMARK BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 265. DENMARK BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 266. DENMARK BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 267. DENMARK BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 268. DENMARK BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 269. EGYPT BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. EGYPT BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 271. EGYPT BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 272. EGYPT BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 273. EGYPT BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 274. EGYPT BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 275. EGYPT BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 276. EGYPT BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. EGYPT BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 278. EGYPT BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 279. FINLAND BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. FINLAND BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 281. FINLAND BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 282. FINLAND BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 283. FINLAND BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 284. FINLAND BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 285. FINLAND BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 286. FINLAND BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 287. FINLAND BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 288. FINLAND BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 289. FRANCE BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. FRANCE BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 291. FRANCE BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 292. FRANCE BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 293. FRANCE BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 294. FRANCE BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 295. FRANCE BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 296. FRANCE BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 297. FRANCE BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 298. FRANCE BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 299. GERMANY BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 300. GERMANY BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 301. GERMANY BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 302. GERMANY BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 303. GERMANY BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 304. GERMANY BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 305. GERMANY BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 306. GERMANY BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 307. GERMANY BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 308. GERMANY BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 309. ISRAEL BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 310. ISRAEL BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 311. ISRAEL BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 312. ISRAEL BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 313. ISRAEL BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 314. ISRAEL BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 315. ISRAEL BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 316. ISRAEL BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 317. ISRAEL BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 318. ISRAEL BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 319. ITALY BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 320. ITALY BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 321. ITALY BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 322. ITALY BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 323. ITALY BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 324. ITALY BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 325. ITALY BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 326. ITALY BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 327. ITALY BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 328. ITALY BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 329. NETHERLANDS BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 330. NETHERLANDS BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 331. NETHERLANDS BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 332. NETHERLANDS BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 333. NETHERLANDS BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 334. NETHERLANDS BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 335. NETHERLANDS BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 336. NETHERLANDS BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 337. NETHERLANDS BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 338. NETHERLANDS BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 339. NIGERIA BIOLOGICS